share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股sec公告 ·  05/18 05:18
牛牛AI助理已提取核心訊息
Senti Biosciences, Inc. has announced a significant change in its executive leadership, effective May 14, 2024. Timothy Lu, M.D., Ph.D., who has been serving as both the Chief Executive Officer and President, stepped down from his role as President. Kanya Rajangam, M.D., Ph.D., previously the Head of Research and Development and Chief Medical Officer at Senti Biosciences, has been appointed as the new President. Dr. Lu will continue in his capacity as CEO of the company. Dr. Rajangam's extensive experience in the biopharmaceutical industry includes roles at various other companies such as Nkarta, Inc., Atara Biotherapeutics, and Nektar Therapeutics. Her appointment is part of a planned succession, and she has no familial or transactional relationships that require disclosure under SEC regulations. The terms of Dr. Rajangam's employment were detailed in an offer letter filed with the SEC in May 2023, which includes her compensation, bonus eligibility, stock options, and severance benefits.
Senti Biosciences, Inc. has announced a significant change in its executive leadership, effective May 14, 2024. Timothy Lu, M.D., Ph.D., who has been serving as both the Chief Executive Officer and President, stepped down from his role as President. Kanya Rajangam, M.D., Ph.D., previously the Head of Research and Development and Chief Medical Officer at Senti Biosciences, has been appointed as the new President. Dr. Lu will continue in his capacity as CEO of the company. Dr. Rajangam's extensive experience in the biopharmaceutical industry includes roles at various other companies such as Nkarta, Inc., Atara Biotherapeutics, and Nektar Therapeutics. Her appointment is part of a planned succession, and she has no familial or transactional relationships that require disclosure under SEC regulations. The terms of Dr. Rajangam's employment were detailed in an offer letter filed with the SEC in May 2023, which includes her compensation, bonus eligibility, stock options, and severance benefits.
森蒂生物科學公司宣佈其執行領導層的重大變動，自2024年5月14日起生效。曾擔任首席執行官兼總裁的盧****醫學博士，已辭去總裁一職。曾任Senti Biosciences研發主管兼首席醫學官的Kanya Rajangam醫學博士、博士被任命爲新總裁。盧博士將繼續擔任公司首席執行官的職務。拉詹甘博士在生物製藥行業的豐富經驗包括在Nkarta, Inc.、Atara Biotherapeutics和Nektar Therapeutics等其他多家公司任職。她的任命是計劃繼任的一部分，根據美國證券交易委員會的規定，她沒有需要披露的家庭或交易關係。Rajangam博士在2023年5月向美國證券交易委員會提交的錄用信中詳細介紹了她的僱傭條款，其中包括她的薪酬、獎金資格、股票期權和遣散費。
森蒂生物科學公司宣佈其執行領導層的重大變動，自2024年5月14日起生效。曾擔任首席執行官兼總裁的盧****醫學博士，已辭去總裁一職。曾任Senti Biosciences研發主管兼首席醫學官的Kanya Rajangam醫學博士、博士被任命爲新總裁。盧博士將繼續擔任公司首席執行官的職務。拉詹甘博士在生物製藥行業的豐富經驗包括在Nkarta, Inc.、Atara Biotherapeutics和Nektar Therapeutics等其他多家公司任職。她的任命是計劃繼任的一部分，根據美國證券交易委員會的規定，她沒有需要披露的家庭或交易關係。Rajangam博士在2023年5月向美國證券交易委員會提交的錄用信中詳細介紹了她的僱傭條款，其中包括她的薪酬、獎金資格、股票期權和遣散費。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。